Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 3
2003 4
2004 4
2005 8
2006 9
2007 2
2008 14
2009 10
2010 19
2011 24
2012 28
2013 18
2014 19
2015 32
2016 31
2017 31
2018 33
2019 52
2020 57
2021 83
2022 79
2023 90
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

592 results

Results by year

Filters applied: . Clear all
Page 1
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population.
Tangri N, Ferguson T, Leon SJ, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Farjat AE, Farag YMK, Schloemer P, Lawatscheck R, Rohwedder K, Bakris GL. Tangri N, et al. Among authors: rossing p. Clin Kidney J. 2024 Mar 6;17(4):sfae052. doi: 10.1093/ckj/sfae052. eCollection 2024 Apr. Clin Kidney J. 2024. PMID: 38650758 Free PMC article.
Circulating metabolomic markers in association with overall burden of microvascular complications in type 1 diabetes.
Rotbain Curovic V, Sørland BA, Hansen TW, Jain SY, Sulek K, Mattila IM, Frimodt-Moller M, Trost K, Legido-Quigley C, Theilade S, Tofte N, Winther SA, Hansen CS, Rossing P, Ahluwalia TS. Rotbain Curovic V, et al. Among authors: rossing p. BMJ Open Diabetes Res Care. 2024 Apr 11;12(2):e003973. doi: 10.1136/bmjdrc-2023-003973. BMJ Open Diabetes Res Care. 2024. PMID: 38604732 Free PMC article.
Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial.
Zhang Z, Heerspink HJL, Chertow GM, Correa-Rotter R, Gasparrini A, Jongs N, Langkilde AM, McMurray JJV, Mistry MN, Rossing P, Toto RD, Vart P, Nitsch D, Wheeler DC, Caplin B. Zhang Z, et al. Among authors: rossing p. Lancet Planet Health. 2024 Apr;8(4):e225-e233. doi: 10.1016/S2542-5196(24)00026-3. Lancet Planet Health. 2024. PMID: 38580424 Free article. Clinical Trial.
Combination therapy for kidney disease in people with diabetes mellitus.
van Raalte DH, Bjornstad P, Cherney DZI, de Boer IH, Fioretto P, Gordin D, Persson F, Rosas SE, Rossing P, Schaub JA, Tuttle K, Waikar SS, Heerspink HJL. van Raalte DH, et al. Among authors: rossing p. Nat Rev Nephrol. 2024 Apr 3. doi: 10.1038/s41581-024-00827-z. Online ahead of print. Nat Rev Nephrol. 2024. PMID: 38570632 Review.
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.
Bansal S, Canziani MEF, Birne R, Anker SD, Bakris GL, Filippatos G, Rossing P, Ruilope LM, Farjat AE, Kolkhof P, Lage A, Brinker M, Pitt B. Bansal S, et al. Among authors: rossing p. BMJ Open. 2024 Mar 19;14(3):e076444. doi: 10.1136/bmjopen-2023-076444. BMJ Open. 2024. PMID: 38508632 Free PMC article. Clinical Trial.
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.
Schnell O, Barnard-Kelly K, Battelino T, Ceriello A, Larsson HE, Fernández-Fernández B, Forst T, Frias JP, Gavin JR 3rd, Giorgino F, Groop PH, Heerspink HJL, Herzig S, Hummel M, Huntley G, Ibrahim M, Itzhak B, Jacob S, Ji L, Kosiborod M, Lalic N, Macieira S, Malik RA, Mankovsky B, Marx N, Mathieu C, Müller TD, Ray K, Rodbard HW, Rossing P, Rydén L, Schumm-Draeger PM, Schwarz P, Škrha J, Snoek F, Tacke F, Taylor B, Jeppesen BT, Tesfaye S, Topsever P, Vilsbøll T, Yu X, Standl E. Schnell O, et al. Among authors: rossing p. Cardiovasc Diabetol. 2024 Mar 19;23(1):104. doi: 10.1186/s12933-024-02180-8. Cardiovasc Diabetol. 2024. PMID: 38504284 Free PMC article.
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
Bornstein SR, de Zeeuw D, Heerspink HJL, Schulze F, Cronin L, Wenz A, Tuttle KR, Hadjadj S, Rossing P. Bornstein SR, et al. Among authors: rossing p. Diabetes Obes Metab. 2024 Mar 18. doi: 10.1111/dom.15518. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38497241
Performance of new and panel CKD-EPI equations in European adults with type 2 diabetes.
Iversen E, Christensen KM, Walls AB, Eickhoff MK, von Scholten BJ, Frimodt-Møller M, Hansen TW, Persson F, Rossing P, Rotbain Curovic V, Houlind MB. Iversen E, et al. Among authors: rossing p. Diabetes Obes Metab. 2024 Mar 6. doi: 10.1111/dom.15536. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38449081 No abstract available.
592 results